Substance Use Disorder Following Consumption of a Novel Synthetic 7-Hydroxymitragynine Product
The MOR selectivity and brief duration of action of some 7-OH formulations support our observation that repeated use may lead to physical dependence. Standard laboratory testing can detect mitragynine but not 7-OH due to its relatively shorter half-life, an issue that may confuse semi-synthetic 7-OH use with kratom. Novel 7-OH products are not kratom. The potency of 7-OH places unwitting consumers who may believe they are using kratom, not a partial MOR agonist, at risk.
Authors
- Edward W. Boyer (ORCID: https://orcid.org/0000-0002-5884-0315)
- Raju S. Kanumuri (ORCID: https://orcid.org/0000-0002-6087-6587)
- Kirsten E. Smith (ORCID: https://orcid.org/0000-0002-9278-1830)
- Abhisheak Sharma (ORCID: https://orcid.org/0000-0003-0553-4039)
- Brandon Reif
- Alek Adkins
Institutions
- Nationwide Children's Hospital (US)
- Johns Hopkins University (US)
- American Association of Colleges of Pharmacy (US)
- School of the Art Institute of Chicago (US)
- Wright State University (US)
- Johns Hopkins Medicine (US)
- University of Florida (US)
- Behavioral Pharma (United States) (US)
- Smiths Detection (United States) (US)
- The Ohio State University (US)
- Florida College (US)
Publication Details
- Journal
- Journal of Addiction Medicine
- Published
- 2025-11-05
- DOI
- https://doi.org/10.1097/adm.0000000000001603
- Citations
- 2
- Primary Topic
- Alkaloids: synthesis and pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 3.11